Literature DB >> 12142562

Tricarboxylic acid cycle substrates prevent PARP-mediated death of neurons and astrocytes.

Weihai Ying1, Yongmei Chen, Conrad C Alano, Raymond A Swanson.   

Abstract

The DNA repair enzyme, poly(ADP-ribose) polymerase-1 (PARP1), contributes to cell death during ischemia/reperfusion when extensively activated by DNA damage. The cell death resulting from PARP1 activation is linked to NAD+ depletion and energy failure, but the intervening steps are not well understood. Because glycolysis requires cytosolic NAD+, the authors tested whether PARP1 activation impairs glycolytic flux and whether substrates that bypass glycolysis can rescue cells after PARP1 activation. PARP1 was activated in mouse cortical astrocyte and astrocyte-neuron cocultures with the DNA alkylating agent, N-methyl-N'-nitro-N-nitrosoguanidine (MNNG). Studies using the 2-deoxyglucose method confirmed that glycolytic flux was reduced by more than 90% in MNNG-treated cultures. The addition of 5 mmol/L of alpha-ketoglutarate, 5 mmol/L pyruvate, or other mitochondrial substrates to the cultures after MNNG treatment reduced cell death from approximately 70% to near basal levels, while PARP inhibitors and excess glucose had negligible effects. The mitochondrial substrates significantly reduced cell death, with delivery delayed up to 2 hours after MNNG washout. The findings suggest that impaired glycolytic flux is an important factor contributing to PARP1-mediated cell death. Delivery of alternative substrates may be a promising strategy for delayed treatment of PARP1-mediated cell death in ischemia and other disorders.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12142562     DOI: 10.1097/00004647-200207000-00002

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  43 in total

1.  Vincristine attenuates N-methyl-N'-nitro-N-nitrosoguanidine-induced poly-(ADP) ribose polymerase activity in cardiomyocytes.

Authors:  Jianqing Zhang; Kanu Chatterjee; Conrad C Alano; Mikaila A Kalinowski; Norman Honbo; Joel S Karliner
Journal:  J Cardiovasc Pharmacol       Date:  2010-03       Impact factor: 3.105

Review 2.  Role of nitrosative stress in the pathogenesis of diabetic vascular dysfunction.

Authors:  Csaba Szabo
Journal:  Br J Pharmacol       Date:  2009-02-06       Impact factor: 8.739

3.  NAD+ depletion is necessary and sufficient for poly(ADP-ribose) polymerase-1-mediated neuronal death.

Authors:  Conrad C Alano; Philippe Garnier; Weihai Ying; Youichirou Higashi; Tiina M Kauppinen; Raymond A Swanson
Journal:  J Neurosci       Date:  2010-02-24       Impact factor: 6.167

4.  Poly(ADP-ribose) polymerase-dependent energy depletion occurs through inhibition of glycolysis.

Authors:  Shaida A Andrabi; George K E Umanah; Calvin Chang; Daniel A Stevens; Senthilkumar S Karuppagounder; Jean-Philippe Gagné; Guy G Poirier; Valina L Dawson; Ted M Dawson
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-01       Impact factor: 11.205

Review 5.  The PARP family: insights into functional aspects of poly (ADP-ribose) polymerase-1 in cell growth and survival.

Authors:  T Jubin; A Kadam; M Jariwala; S Bhatt; S Sutariya; A R Gani; S Gautam; R Begum
Journal:  Cell Prolif       Date:  2016-06-22       Impact factor: 6.831

Review 6.  Poly(ADP-ribose) polymerase-1 in amyloid beta toxicity and Alzheimer's disease.

Authors:  Joanna B Strosznajder; Grzegorz A Czapski; Agata Adamczyk; Robert P Strosznajder
Journal:  Mol Neurobiol       Date:  2012-03-20       Impact factor: 5.590

Review 7.  Mitochondrial dysfunction and NAD(+) metabolism alterations in the pathophysiology of acute brain injury.

Authors:  Katrina Owens; Ji H Park; Rosemary Schuh; Tibor Kristian
Journal:  Transl Stroke Res       Date:  2013-08-10       Impact factor: 6.829

Review 8.  Mitochondrial dysfunction induced by nuclear poly(ADP-ribose) polymerase-1: a treatable cause of cell death in stroke.

Authors:  Paul Baxter; Yanting Chen; Yun Xu; Raymond A Swanson
Journal:  Transl Stroke Res       Date:  2013-09-07       Impact factor: 6.829

Review 9.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

Review 10.  Crosstalk between poly(ADP-ribose) polymerase and sirtuin enzymes.

Authors:  Carles Cantó; Anthony A Sauve; Peter Bai
Journal:  Mol Aspects Med       Date:  2013-01-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.